| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 33,424,000 | 28,190,000 | 26,323,000 | 25,979,000 | 25,424,000 |
| Sales Growth | +18.57% | +7.09% | +1.32% | +2.18% | +8.83% |
| Net Income | 4,090,000 | 6,717,000 | 6,552,000 | 5,893,000 | 7,264,000 |
| Net Income Growth | -39.11% | +2.52% | +11.18% | -18.87% | -7.37% |
Amgen Inc (AMGN)
302.20 x 1 305.60 x 1
Post-market by (Cboe BZX)
305.71 -1.15 (-0.37%) 03/26/25 [NASDAQ]
302.20 x 1 305.60 x 1
Post-market 305.60 -0.11 (-0.04%) 17:37 ET
for Wed, Mar 26th, 2025
Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp & Neulasta and also a biosimilar drug, Prolia/Xgeva. The acquisition of Immunex Corp gave Amgen access to the multi-blockbuster drug, Enbrel. Other products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Lumakras/Lumykras, Kanjinti, Mvasi & Amgevita biosimilars. Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. The erythropoiesis-stimulating agents and granulocyte colony-stimulating factor franchise comprise Epogen/Aranesp and Neupogen/Neulasta respectively. Biosimilar drugs are also a key part of Amgen's growth strategy.
Fiscal Year End Date: 12/31